Vanguard Global Advisers’s Cartesian Therapeutics RNAC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$26.5K Buy
3,677
+47
+1% +$409 ﹤0.01% 3271
2026
Q2
$37.8K Hold
3,630
– – ﹤0.01% 3158
2026
Q1
$22.3K Buy
+3,630
New +$25.9K ﹤0.01% 3272

Other funds holding RNAC

Vanguard Global Advisers's RNAC Position: Q3 2026 in Review

Vanguard Global Advisers increased its Cartesian Therapeutics (RNAC) stake by 1.3% in Q3 2026, buying an estimated $409 and bringing the position to 3,677 shares worth $26.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3271.

Vanguard Global Advisers first reported a position in RNAC in Q1 2026 and has held it in 3 quarters since. The position peaked at $37.8K in Q2 2026. 100 funds tracked by Wall St. Rank hold RNAC as of Q3 2026.

  • Vanguard Global Advisers held 3,677 shares of Cartesian Therapeutics worth $26.5K as of Q3 2026.
  • Vanguard Global Advisers bought 47 Cartesian Therapeutics shares in Q3 2026, an estimated $409.
  • Cartesian Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #3271 holding.
  • Vanguard Global Advisers first reported a position in Cartesian Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Global Advisers's Cartesian Therapeutics position peaked at $37.8K in Q2 2026.
  • 100 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q3 2026.

Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.